nodes	percent_of_prediction	percent_of_DWPC	metapath
Brinzolamide—CA6—saliva-secreting gland—thyroid cancer	0.0149	0.123	CbGeAlD
Brinzolamide—CA7—trachea—thyroid cancer	0.0119	0.0982	CbGeAlD
Brinzolamide—CA6—head—thyroid cancer	0.00806	0.0668	CbGeAlD
Brinzolamide—CA4—neck—thyroid cancer	0.00792	0.0657	CbGeAlD
Brinzolamide—CA12—trachea—thyroid cancer	0.0077	0.0638	CbGeAlD
Brinzolamide—CA2—neck—thyroid cancer	0.00657	0.0544	CbGeAlD
Brinzolamide—CA4—saliva-secreting gland—thyroid cancer	0.00618	0.0512	CbGeAlD
Brinzolamide—CA5B—thyroid gland—thyroid cancer	0.00546	0.0453	CbGeAlD
Brinzolamide—CA12—head—thyroid cancer	0.0054	0.0448	CbGeAlD
Brinzolamide—CA2—saliva-secreting gland—thyroid cancer	0.00512	0.0425	CbGeAlD
Brinzolamide—CA5B—head—thyroid cancer	0.00485	0.0402	CbGeAlD
Brinzolamide—CA4—trachea—thyroid cancer	0.00477	0.0395	CbGeAlD
Brinzolamide—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.0044	0.00514	CcSEcCtD
Brinzolamide—Dry mouth—Vandetanib—thyroid cancer	0.00433	0.00506	CcSEcCtD
Brinzolamide—CA1—head—thyroid cancer	0.00428	0.0355	CbGeAlD
Brinzolamide—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00424	0.00496	CcSEcCtD
Brinzolamide—Epistaxis—Sorafenib—thyroid cancer	0.00423	0.00495	CcSEcCtD
Brinzolamide—Keratitis—Doxorubicin—thyroid cancer	0.00423	0.00494	CcSEcCtD
Brinzolamide—Infection—Vandetanib—thyroid cancer	0.00422	0.00493	CcSEcCtD
Brinzolamide—Nervous system disorder—Vandetanib—thyroid cancer	0.00416	0.00486	CcSEcCtD
Brinzolamide—Skin disorder—Vandetanib—thyroid cancer	0.00412	0.00482	CcSEcCtD
Brinzolamide—Urinary tract disorder—Sorafenib—thyroid cancer	0.00398	0.00465	CcSEcCtD
Brinzolamide—Connective tissue disorder—Sorafenib—thyroid cancer	0.00396	0.00463	CcSEcCtD
Brinzolamide—CA2—trachea—thyroid cancer	0.00395	0.0328	CbGeAlD
Brinzolamide—Urethral disorder—Sorafenib—thyroid cancer	0.00395	0.00462	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00387	0.00452	CcSEcCtD
Brinzolamide—Insomnia—Vandetanib—thyroid cancer	0.00384	0.00449	CcSEcCtD
Brinzolamide—Paraesthesia—Vandetanib—thyroid cancer	0.00381	0.00445	CcSEcCtD
Brinzolamide—Dyspnoea—Vandetanib—thyroid cancer	0.00378	0.00442	CcSEcCtD
Brinzolamide—CA4—thyroid gland—thyroid cancer	0.00377	0.0313	CbGeAlD
Brinzolamide—Tinnitus—Sorafenib—thyroid cancer	0.00376	0.00439	CcSEcCtD
Brinzolamide—Cardiac disorder—Sorafenib—thyroid cancer	0.00374	0.00437	CcSEcCtD
Brinzolamide—Dyspepsia—Vandetanib—thyroid cancer	0.00374	0.00437	CcSEcCtD
Brinzolamide—Decreased appetite—Vandetanib—thyroid cancer	0.00369	0.00431	CcSEcCtD
Brinzolamide—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00366	0.00428	CcSEcCtD
Brinzolamide—Ageusia—Epirubicin—thyroid cancer	0.00366	0.00428	CcSEcCtD
Brinzolamide—Fatigue—Vandetanib—thyroid cancer	0.00366	0.00428	CcSEcCtD
Brinzolamide—Angiopathy—Sorafenib—thyroid cancer	0.00366	0.00427	CcSEcCtD
Brinzolamide—Immune system disorder—Sorafenib—thyroid cancer	0.00364	0.00425	CcSEcCtD
Brinzolamide—Mediastinal disorder—Sorafenib—thyroid cancer	0.00363	0.00424	CcSEcCtD
Brinzolamide—Pain—Vandetanib—thyroid cancer	0.00363	0.00424	CcSEcCtD
Brinzolamide—Arrhythmia—Sorafenib—thyroid cancer	0.0036	0.00421	CcSEcCtD
Brinzolamide—Alopecia—Sorafenib—thyroid cancer	0.00356	0.00416	CcSEcCtD
Brinzolamide—Mental disorder—Sorafenib—thyroid cancer	0.00353	0.00413	CcSEcCtD
Brinzolamide—Erythema—Sorafenib—thyroid cancer	0.00351	0.0041	CcSEcCtD
Brinzolamide—Malnutrition—Sorafenib—thyroid cancer	0.00351	0.0041	CcSEcCtD
Brinzolamide—Dysgeusia—Sorafenib—thyroid cancer	0.00343	0.00401	CcSEcCtD
Brinzolamide—CA5B—lymph node—thyroid cancer	0.00339	0.0281	CbGeAlD
Brinzolamide—Ageusia—Doxorubicin—thyroid cancer	0.00339	0.00396	CcSEcCtD
Brinzolamide—Muscle spasms—Sorafenib—thyroid cancer	0.00337	0.00394	CcSEcCtD
Brinzolamide—CA4—head—thyroid cancer	0.00335	0.0277	CbGeAlD
Brinzolamide—Lacrimation increased—Epirubicin—thyroid cancer	0.00322	0.00376	CcSEcCtD
Brinzolamide—CA2—thyroid gland—thyroid cancer	0.00313	0.0259	CbGeAlD
Brinzolamide—Cough—Sorafenib—thyroid cancer	0.00306	0.00358	CcSEcCtD
Brinzolamide—Asthenia—Vandetanib—thyroid cancer	0.00304	0.00356	CcSEcCtD
Brinzolamide—Hypertension—Sorafenib—thyroid cancer	0.00303	0.00354	CcSEcCtD
Brinzolamide—Pruritus—Vandetanib—thyroid cancer	0.003	0.00351	CcSEcCtD
Brinzolamide—CA1—lymph node—thyroid cancer	0.003	0.0248	CbGeAlD
Brinzolamide—Myalgia—Sorafenib—thyroid cancer	0.00299	0.00349	CcSEcCtD
Brinzolamide—Arthralgia—Sorafenib—thyroid cancer	0.00299	0.00349	CcSEcCtD
Brinzolamide—Lacrimation increased—Doxorubicin—thyroid cancer	0.00298	0.00348	CcSEcCtD
Brinzolamide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00297	0.00347	CcSEcCtD
Brinzolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EPO—thyroid cancer	0.00295	0.125	CbGpPWpGaD
Brinzolamide—Dry mouth—Sorafenib—thyroid cancer	0.00292	0.00341	CcSEcCtD
Brinzolamide—Diarrhoea—Vandetanib—thyroid cancer	0.0029	0.00339	CcSEcCtD
Brinzolamide—Infection—Sorafenib—thyroid cancer	0.00284	0.00332	CcSEcCtD
Brinzolamide—Nervous system disorder—Sorafenib—thyroid cancer	0.00281	0.00328	CcSEcCtD
Brinzolamide—Dizziness—Vandetanib—thyroid cancer	0.00281	0.00328	CcSEcCtD
Brinzolamide—Skin disorder—Sorafenib—thyroid cancer	0.00278	0.00325	CcSEcCtD
Brinzolamide—CA2—head—thyroid cancer	0.00277	0.023	CbGeAlD
Brinzolamide—Dry eye—Epirubicin—thyroid cancer	0.00274	0.0032	CcSEcCtD
Brinzolamide—Oesophagitis—Epirubicin—thyroid cancer	0.00271	0.00317	CcSEcCtD
Brinzolamide—Vomiting—Vandetanib—thyroid cancer	0.0027	0.00315	CcSEcCtD
Brinzolamide—Rash maculo-papular—Epirubicin—thyroid cancer	0.0027	0.00315	CcSEcCtD
Brinzolamide—Rash—Vandetanib—thyroid cancer	0.00268	0.00313	CcSEcCtD
Brinzolamide—Dermatitis—Vandetanib—thyroid cancer	0.00267	0.00312	CcSEcCtD
Brinzolamide—Headache—Vandetanib—thyroid cancer	0.00266	0.00311	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00261	0.00305	CcSEcCtD
Brinzolamide—Hypertonia—Epirubicin—thyroid cancer	0.0026	0.00304	CcSEcCtD
Brinzolamide—Abnormal vision—Epirubicin—thyroid cancer	0.00259	0.00302	CcSEcCtD
Brinzolamide—Dyspnoea—Sorafenib—thyroid cancer	0.00255	0.00298	CcSEcCtD
Brinzolamide—Dry eye—Doxorubicin—thyroid cancer	0.00253	0.00296	CcSEcCtD
Brinzolamide—Nausea—Vandetanib—thyroid cancer	0.00252	0.00295	CcSEcCtD
Brinzolamide—Dyspepsia—Sorafenib—thyroid cancer	0.00252	0.00294	CcSEcCtD
Brinzolamide—Oesophagitis—Doxorubicin—thyroid cancer	0.00251	0.00293	CcSEcCtD
Brinzolamide—Rash maculo-papular—Doxorubicin—thyroid cancer	0.00249	0.00291	CcSEcCtD
Brinzolamide—Decreased appetite—Sorafenib—thyroid cancer	0.00249	0.00291	CcSEcCtD
Brinzolamide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00247	0.00289	CcSEcCtD
Brinzolamide—Fatigue—Sorafenib—thyroid cancer	0.00247	0.00288	CcSEcCtD
Brinzolamide—Pain—Sorafenib—thyroid cancer	0.00245	0.00286	CcSEcCtD
Brinzolamide—Hypertonia—Doxorubicin—thyroid cancer	0.0024	0.00281	CcSEcCtD
Brinzolamide—Abnormal vision—Doxorubicin—thyroid cancer	0.00239	0.0028	CcSEcCtD
Brinzolamide—Eye pain—Epirubicin—thyroid cancer	0.00238	0.00279	CcSEcCtD
Brinzolamide—CA4—lymph node—thyroid cancer	0.00234	0.0194	CbGeAlD
Brinzolamide—Urticaria—Sorafenib—thyroid cancer	0.00227	0.00266	CcSEcCtD
Brinzolamide—Eye pain—Doxorubicin—thyroid cancer	0.00221	0.00258	CcSEcCtD
Brinzolamide—Pain in extremity—Epirubicin—thyroid cancer	0.00215	0.00252	CcSEcCtD
Brinzolamide—Diplopia—Epirubicin—thyroid cancer	0.00215	0.00252	CcSEcCtD
Brinzolamide—Hypersensitivity—Sorafenib—thyroid cancer	0.00211	0.00246	CcSEcCtD
Brinzolamide—Asthenia—Sorafenib—thyroid cancer	0.00205	0.0024	CcSEcCtD
Brinzolamide—Pruritus—Sorafenib—thyroid cancer	0.00203	0.00237	CcSEcCtD
Brinzolamide—Pain in extremity—Doxorubicin—thyroid cancer	0.00199	0.00233	CcSEcCtD
Brinzolamide—Diplopia—Doxorubicin—thyroid cancer	0.00199	0.00233	CcSEcCtD
Brinzolamide—Liver function test abnormal—Epirubicin—thyroid cancer	0.00199	0.00232	CcSEcCtD
Brinzolamide—Abdominal pain upper—Epirubicin—thyroid cancer	0.00197	0.0023	CcSEcCtD
Brinzolamide—Diarrhoea—Sorafenib—thyroid cancer	0.00196	0.00229	CcSEcCtD
Brinzolamide—Breast disorder—Epirubicin—thyroid cancer	0.00195	0.00227	CcSEcCtD
Brinzolamide—CA2—lymph node—thyroid cancer	0.00194	0.0161	CbGeAlD
Brinzolamide—Nasopharyngitis—Epirubicin—thyroid cancer	0.00192	0.00225	CcSEcCtD
Brinzolamide—Dizziness—Sorafenib—thyroid cancer	0.00189	0.00221	CcSEcCtD
Brinzolamide—Asthma—Epirubicin—thyroid cancer	0.00186	0.00217	CcSEcCtD
Brinzolamide—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00184	0.00215	CcSEcCtD
Brinzolamide—Vomiting—Sorafenib—thyroid cancer	0.00182	0.00213	CcSEcCtD
Brinzolamide—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00182	0.00213	CcSEcCtD
Brinzolamide—Angina pectoris—Epirubicin—thyroid cancer	0.00181	0.00212	CcSEcCtD
Brinzolamide—Rash—Sorafenib—thyroid cancer	0.0018	0.00211	CcSEcCtD
Brinzolamide—Dermatitis—Sorafenib—thyroid cancer	0.0018	0.00211	CcSEcCtD
Brinzolamide—Breast disorder—Doxorubicin—thyroid cancer	0.0018	0.0021	CcSEcCtD
Brinzolamide—Headache—Sorafenib—thyroid cancer	0.00179	0.0021	CcSEcCtD
Brinzolamide—Bronchitis—Epirubicin—thyroid cancer	0.00179	0.00209	CcSEcCtD
Brinzolamide—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00178	0.00208	CcSEcCtD
Brinzolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—HIF1A—thyroid cancer	0.00176	0.0743	CbGpPWpGaD
Brinzolamide—Asthma—Doxorubicin—thyroid cancer	0.00172	0.00201	CcSEcCtD
Brinzolamide—Pollakiuria—Epirubicin—thyroid cancer	0.00172	0.00201	CcSEcCtD
Brinzolamide—Nausea—Sorafenib—thyroid cancer	0.0017	0.00199	CcSEcCtD
Brinzolamide—Angina pectoris—Doxorubicin—thyroid cancer	0.00168	0.00196	CcSEcCtD
Brinzolamide—Infestation NOS—Epirubicin—thyroid cancer	0.00166	0.00194	CcSEcCtD
Brinzolamide—Infestation—Epirubicin—thyroid cancer	0.00166	0.00194	CcSEcCtD
Brinzolamide—Bronchitis—Doxorubicin—thyroid cancer	0.00166	0.00193	CcSEcCtD
Brinzolamide—Conjunctivitis—Epirubicin—thyroid cancer	0.00161	0.00188	CcSEcCtD
Brinzolamide—Pollakiuria—Doxorubicin—thyroid cancer	0.00159	0.00186	CcSEcCtD
Brinzolamide—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00157	0.00183	CcSEcCtD
Brinzolamide—Epistaxis—Epirubicin—thyroid cancer	0.00156	0.00183	CcSEcCtD
Brinzolamide—Sinusitis—Epirubicin—thyroid cancer	0.00156	0.00182	CcSEcCtD
Brinzolamide—Infestation NOS—Doxorubicin—thyroid cancer	0.00153	0.00179	CcSEcCtD
Brinzolamide—Infestation—Doxorubicin—thyroid cancer	0.00153	0.00179	CcSEcCtD
Brinzolamide—Bradycardia—Epirubicin—thyroid cancer	0.00152	0.00177	CcSEcCtD
Brinzolamide—Rhinitis—Epirubicin—thyroid cancer	0.00149	0.00174	CcSEcCtD
Brinzolamide—Conjunctivitis—Doxorubicin—thyroid cancer	0.00149	0.00174	CcSEcCtD
Brinzolamide—Hypoaesthesia—Epirubicin—thyroid cancer	0.00148	0.00173	CcSEcCtD
Brinzolamide—Pharyngitis—Epirubicin—thyroid cancer	0.00148	0.00173	CcSEcCtD
Brinzolamide—Urinary tract disorder—Epirubicin—thyroid cancer	0.00147	0.00172	CcSEcCtD
Brinzolamide—Oedema peripheral—Epirubicin—thyroid cancer	0.00147	0.00171	CcSEcCtD
Brinzolamide—Connective tissue disorder—Epirubicin—thyroid cancer	0.00146	0.00171	CcSEcCtD
Brinzolamide—Urethral disorder—Epirubicin—thyroid cancer	0.00146	0.00171	CcSEcCtD
Brinzolamide—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00145	0.0017	CcSEcCtD
Brinzolamide—Epistaxis—Doxorubicin—thyroid cancer	0.00145	0.00169	CcSEcCtD
Brinzolamide—Sinusitis—Doxorubicin—thyroid cancer	0.00144	0.00168	CcSEcCtD
Brinzolamide—Visual impairment—Epirubicin—thyroid cancer	0.00143	0.00168	CcSEcCtD
Brinzolamide—Bradycardia—Doxorubicin—thyroid cancer	0.0014	0.00164	CcSEcCtD
Brinzolamide—Eye disorder—Epirubicin—thyroid cancer	0.00139	0.00163	CcSEcCtD
Brinzolamide—Tinnitus—Epirubicin—thyroid cancer	0.00139	0.00162	CcSEcCtD
Brinzolamide—Cardiac disorder—Epirubicin—thyroid cancer	0.00138	0.00162	CcSEcCtD
Brinzolamide—Rhinitis—Doxorubicin—thyroid cancer	0.00138	0.00161	CcSEcCtD
Brinzolamide—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00137	0.0016	CcSEcCtD
Brinzolamide—Pharyngitis—Doxorubicin—thyroid cancer	0.00137	0.0016	CcSEcCtD
Brinzolamide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00136	0.00159	CcSEcCtD
Brinzolamide—Oedema peripheral—Doxorubicin—thyroid cancer	0.00136	0.00159	CcSEcCtD
Brinzolamide—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00135	0.00158	CcSEcCtD
Brinzolamide—Angiopathy—Epirubicin—thyroid cancer	0.00135	0.00158	CcSEcCtD
Brinzolamide—Urethral disorder—Doxorubicin—thyroid cancer	0.00135	0.00158	CcSEcCtD
Brinzolamide—Immune system disorder—Epirubicin—thyroid cancer	0.00134	0.00157	CcSEcCtD
Brinzolamide—Mediastinal disorder—Epirubicin—thyroid cancer	0.00134	0.00157	CcSEcCtD
Brinzolamide—Arrhythmia—Epirubicin—thyroid cancer	0.00133	0.00155	CcSEcCtD
Brinzolamide—Visual impairment—Doxorubicin—thyroid cancer	0.00133	0.00155	CcSEcCtD
Brinzolamide—Alopecia—Epirubicin—thyroid cancer	0.00132	0.00154	CcSEcCtD
Brinzolamide—CA9—Cellular response to hypoxia—EPO—thyroid cancer	0.0013	0.0551	CbGpPWpGaD
Brinzolamide—Mental disorder—Epirubicin—thyroid cancer	0.0013	0.00152	CcSEcCtD
Brinzolamide—Malnutrition—Epirubicin—thyroid cancer	0.0013	0.00151	CcSEcCtD
Brinzolamide—Erythema—Epirubicin—thyroid cancer	0.0013	0.00151	CcSEcCtD
Brinzolamide—Eye disorder—Doxorubicin—thyroid cancer	0.00129	0.0015	CcSEcCtD
Brinzolamide—Tinnitus—Doxorubicin—thyroid cancer	0.00128	0.0015	CcSEcCtD
Brinzolamide—Cardiac disorder—Doxorubicin—thyroid cancer	0.00128	0.00149	CcSEcCtD
Brinzolamide—Flatulence—Epirubicin—thyroid cancer	0.00128	0.00149	CcSEcCtD
Brinzolamide—Tension—Epirubicin—thyroid cancer	0.00127	0.00149	CcSEcCtD
Brinzolamide—Dysgeusia—Epirubicin—thyroid cancer	0.00127	0.00148	CcSEcCtD
Brinzolamide—Nervousness—Epirubicin—thyroid cancer	0.00126	0.00147	CcSEcCtD
Brinzolamide—Back pain—Epirubicin—thyroid cancer	0.00125	0.00147	CcSEcCtD
Brinzolamide—Angiopathy—Doxorubicin—thyroid cancer	0.00125	0.00146	CcSEcCtD
Brinzolamide—Muscle spasms—Epirubicin—thyroid cancer	0.00125	0.00146	CcSEcCtD
Brinzolamide—Immune system disorder—Doxorubicin—thyroid cancer	0.00124	0.00145	CcSEcCtD
Brinzolamide—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00124	0.00145	CcSEcCtD
Brinzolamide—Arrhythmia—Doxorubicin—thyroid cancer	0.00123	0.00144	CcSEcCtD
Brinzolamide—Vision blurred—Epirubicin—thyroid cancer	0.00122	0.00143	CcSEcCtD
Brinzolamide—Alopecia—Doxorubicin—thyroid cancer	0.00122	0.00142	CcSEcCtD
Brinzolamide—Mental disorder—Doxorubicin—thyroid cancer	0.00121	0.00141	CcSEcCtD
Brinzolamide—Ill-defined disorder—Epirubicin—thyroid cancer	0.0012	0.00141	CcSEcCtD
Brinzolamide—Erythema—Doxorubicin—thyroid cancer	0.0012	0.0014	CcSEcCtD
Brinzolamide—Malnutrition—Doxorubicin—thyroid cancer	0.0012	0.0014	CcSEcCtD
Brinzolamide—Agitation—Epirubicin—thyroid cancer	0.00119	0.00139	CcSEcCtD
Brinzolamide—Flatulence—Doxorubicin—thyroid cancer	0.00118	0.00138	CcSEcCtD
Brinzolamide—Tension—Doxorubicin—thyroid cancer	0.00118	0.00138	CcSEcCtD
Brinzolamide—Dysgeusia—Doxorubicin—thyroid cancer	0.00117	0.00137	CcSEcCtD
Brinzolamide—Malaise—Epirubicin—thyroid cancer	0.00117	0.00137	CcSEcCtD
Brinzolamide—Nervousness—Doxorubicin—thyroid cancer	0.00116	0.00136	CcSEcCtD
Brinzolamide—Vertigo—Epirubicin—thyroid cancer	0.00116	0.00136	CcSEcCtD
Brinzolamide—Back pain—Doxorubicin—thyroid cancer	0.00116	0.00136	CcSEcCtD
Brinzolamide—Muscle spasms—Doxorubicin—thyroid cancer	0.00115	0.00135	CcSEcCtD
Brinzolamide—Palpitations—Epirubicin—thyroid cancer	0.00115	0.00134	CcSEcCtD
Brinzolamide—Cough—Epirubicin—thyroid cancer	0.00113	0.00132	CcSEcCtD
Brinzolamide—Vision blurred—Doxorubicin—thyroid cancer	0.00113	0.00132	CcSEcCtD
Brinzolamide—Hypertension—Epirubicin—thyroid cancer	0.00112	0.00131	CcSEcCtD
Brinzolamide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00111	0.0013	CcSEcCtD
Brinzolamide—Arthralgia—Epirubicin—thyroid cancer	0.0011	0.00129	CcSEcCtD
Brinzolamide—Chest pain—Epirubicin—thyroid cancer	0.0011	0.00129	CcSEcCtD
Brinzolamide—Myalgia—Epirubicin—thyroid cancer	0.0011	0.00129	CcSEcCtD
Brinzolamide—Agitation—Doxorubicin—thyroid cancer	0.0011	0.00129	CcSEcCtD
Brinzolamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.0011	0.00128	CcSEcCtD
Brinzolamide—Discomfort—Epirubicin—thyroid cancer	0.00109	0.00127	CcSEcCtD
Brinzolamide—Malaise—Doxorubicin—thyroid cancer	0.00108	0.00126	CcSEcCtD
Brinzolamide—Dry mouth—Epirubicin—thyroid cancer	0.00108	0.00126	CcSEcCtD
Brinzolamide—Vertigo—Doxorubicin—thyroid cancer	0.00108	0.00126	CcSEcCtD
Brinzolamide—Palpitations—Doxorubicin—thyroid cancer	0.00106	0.00124	CcSEcCtD
Brinzolamide—Infection—Epirubicin—thyroid cancer	0.00105	0.00123	CcSEcCtD
Brinzolamide—Cough—Doxorubicin—thyroid cancer	0.00105	0.00122	CcSEcCtD
Brinzolamide—Nervous system disorder—Epirubicin—thyroid cancer	0.00104	0.00121	CcSEcCtD
Brinzolamide—Hypertension—Doxorubicin—thyroid cancer	0.00104	0.00121	CcSEcCtD
Brinzolamide—Tachycardia—Epirubicin—thyroid cancer	0.00103	0.00121	CcSEcCtD
Brinzolamide—Skin disorder—Epirubicin—thyroid cancer	0.00103	0.0012	CcSEcCtD
Brinzolamide—Arthralgia—Doxorubicin—thyroid cancer	0.00102	0.00119	CcSEcCtD
Brinzolamide—Myalgia—Doxorubicin—thyroid cancer	0.00102	0.00119	CcSEcCtD
Brinzolamide—Chest pain—Doxorubicin—thyroid cancer	0.00102	0.00119	CcSEcCtD
Brinzolamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00101	0.00119	CcSEcCtD
Brinzolamide—Discomfort—Doxorubicin—thyroid cancer	0.00101	0.00118	CcSEcCtD
Brinzolamide—Dry mouth—Doxorubicin—thyroid cancer	0.000999	0.00117	CcSEcCtD
Brinzolamide—Hypotension—Epirubicin—thyroid cancer	0.000989	0.00116	CcSEcCtD
Brinzolamide—Infection—Doxorubicin—thyroid cancer	0.000972	0.00114	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000964	0.00113	CcSEcCtD
Brinzolamide—Nervous system disorder—Doxorubicin—thyroid cancer	0.00096	0.00112	CcSEcCtD
Brinzolamide—Insomnia—Epirubicin—thyroid cancer	0.000957	0.00112	CcSEcCtD
Brinzolamide—Tachycardia—Doxorubicin—thyroid cancer	0.000955	0.00112	CcSEcCtD
Brinzolamide—Skin disorder—Doxorubicin—thyroid cancer	0.000951	0.00111	CcSEcCtD
Brinzolamide—Paraesthesia—Epirubicin—thyroid cancer	0.00095	0.00111	CcSEcCtD
Brinzolamide—Dyspnoea—Epirubicin—thyroid cancer	0.000943	0.0011	CcSEcCtD
Brinzolamide—Somnolence—Epirubicin—thyroid cancer	0.00094	0.0011	CcSEcCtD
Brinzolamide—Dyspepsia—Epirubicin—thyroid cancer	0.000931	0.00109	CcSEcCtD
Brinzolamide—Decreased appetite—Epirubicin—thyroid cancer	0.00092	0.00107	CcSEcCtD
Brinzolamide—Hypotension—Doxorubicin—thyroid cancer	0.000915	0.00107	CcSEcCtD
Brinzolamide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000913	0.00107	CcSEcCtD
Brinzolamide—Fatigue—Epirubicin—thyroid cancer	0.000912	0.00107	CcSEcCtD
Brinzolamide—Pain—Epirubicin—thyroid cancer	0.000905	0.00106	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000892	0.00104	CcSEcCtD
Brinzolamide—Insomnia—Doxorubicin—thyroid cancer	0.000885	0.00103	CcSEcCtD
Brinzolamide—Paraesthesia—Doxorubicin—thyroid cancer	0.000879	0.00103	CcSEcCtD
Brinzolamide—Dyspnoea—Doxorubicin—thyroid cancer	0.000873	0.00102	CcSEcCtD
Brinzolamide—Feeling abnormal—Epirubicin—thyroid cancer	0.000872	0.00102	CcSEcCtD
Brinzolamide—Somnolence—Doxorubicin—thyroid cancer	0.00087	0.00102	CcSEcCtD
Brinzolamide—Dyspepsia—Doxorubicin—thyroid cancer	0.000862	0.00101	CcSEcCtD
Brinzolamide—Decreased appetite—Doxorubicin—thyroid cancer	0.000851	0.000994	CcSEcCtD
Brinzolamide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000845	0.000988	CcSEcCtD
Brinzolamide—Fatigue—Doxorubicin—thyroid cancer	0.000844	0.000986	CcSEcCtD
Brinzolamide—Urticaria—Epirubicin—thyroid cancer	0.00084	0.000982	CcSEcCtD
Brinzolamide—Pain—Doxorubicin—thyroid cancer	0.000837	0.000978	CcSEcCtD
Brinzolamide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000807	0.000943	CcSEcCtD
Brinzolamide—Hypersensitivity—Epirubicin—thyroid cancer	0.000779	0.000911	CcSEcCtD
Brinzolamide—Urticaria—Doxorubicin—thyroid cancer	0.000778	0.000909	CcSEcCtD
Brinzolamide—CA9—Cellular response to hypoxia—HIF1A—thyroid cancer	0.000777	0.0328	CbGpPWpGaD
Brinzolamide—CA9—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000765	0.0323	CbGpPWpGaD
Brinzolamide—Asthenia—Epirubicin—thyroid cancer	0.000759	0.000887	CcSEcCtD
Brinzolamide—Pruritus—Epirubicin—thyroid cancer	0.000748	0.000875	CcSEcCtD
Brinzolamide—Diarrhoea—Epirubicin—thyroid cancer	0.000724	0.000846	CcSEcCtD
Brinzolamide—Hypersensitivity—Doxorubicin—thyroid cancer	0.000721	0.000843	CcSEcCtD
Brinzolamide—Asthenia—Doxorubicin—thyroid cancer	0.000702	0.000821	CcSEcCtD
Brinzolamide—Dizziness—Epirubicin—thyroid cancer	0.0007	0.000818	CcSEcCtD
Brinzolamide—Pruritus—Doxorubicin—thyroid cancer	0.000693	0.000809	CcSEcCtD
Brinzolamide—Vomiting—Epirubicin—thyroid cancer	0.000673	0.000786	CcSEcCtD
Brinzolamide—Diarrhoea—Doxorubicin—thyroid cancer	0.00067	0.000783	CcSEcCtD
Brinzolamide—Rash—Epirubicin—thyroid cancer	0.000667	0.00078	CcSEcCtD
Brinzolamide—Dermatitis—Epirubicin—thyroid cancer	0.000666	0.000779	CcSEcCtD
Brinzolamide—Headache—Epirubicin—thyroid cancer	0.000663	0.000775	CcSEcCtD
Brinzolamide—Dizziness—Doxorubicin—thyroid cancer	0.000647	0.000756	CcSEcCtD
Brinzolamide—Nausea—Epirubicin—thyroid cancer	0.000628	0.000734	CcSEcCtD
Brinzolamide—Vomiting—Doxorubicin—thyroid cancer	0.000622	0.000727	CcSEcCtD
Brinzolamide—Rash—Doxorubicin—thyroid cancer	0.000617	0.000721	CcSEcCtD
Brinzolamide—Dermatitis—Doxorubicin—thyroid cancer	0.000617	0.000721	CcSEcCtD
Brinzolamide—Headache—Doxorubicin—thyroid cancer	0.000613	0.000717	CcSEcCtD
Brinzolamide—CA9—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.0006	0.0254	CbGpPWpGaD
Brinzolamide—Nausea—Doxorubicin—thyroid cancer	0.000581	0.00068	CcSEcCtD
Brinzolamide—CA9—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000374	0.0158	CbGpPWpGaD
Brinzolamide—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000366	0.0155	CbGpPWpGaD
Brinzolamide—CA9—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000357	0.0151	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—MINPP1—thyroid cancer	0.000302	0.0128	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—MINPP1—thyroid cancer	0.000295	0.0125	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—MINPP1—thyroid cancer	0.000295	0.0125	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—MINPP1—thyroid cancer	0.000275	0.0116	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—MINPP1—thyroid cancer	0.000275	0.0116	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—NDUFA13—thyroid cancer	0.000257	0.0109	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—MINPP1—thyroid cancer	0.000255	0.0108	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—NDUFA13—thyroid cancer	0.000251	0.0106	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—NDUFA13—thyroid cancer	0.000251	0.0106	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—CHST14—thyroid cancer	0.000242	0.0102	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—CHST14—thyroid cancer	0.000236	0.00996	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—CHST14—thyroid cancer	0.000236	0.00996	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—NDUFA13—thyroid cancer	0.000234	0.00988	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—NDUFA13—thyroid cancer	0.000234	0.00988	CbGpPWpGaD
Brinzolamide—CA1—C-MYB transcription factor network—PTGS2—thyroid cancer	0.000224	0.00947	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—CHST14—thyroid cancer	0.00022	0.00929	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—CHST14—thyroid cancer	0.00022	0.00929	CbGpPWpGaD
Brinzolamide—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000219	0.00927	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—NDUFA13—thyroid cancer	0.000217	0.00916	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—CHST14—thyroid cancer	0.000204	0.00861	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—MINPP1—thyroid cancer	0.000203	0.00859	CbGpPWpGaD
Brinzolamide—CA1—C-MYB transcription factor network—CCND1—thyroid cancer	0.000202	0.00856	CbGpPWpGaD
Brinzolamide—CA9—Cellular responses to stress—EPO—thyroid cancer	0.000198	0.00837	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—HPGD—thyroid cancer	0.000195	0.00823	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—MINPP1—thyroid cancer	0.000195	0.00823	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—HPGD—thyroid cancer	0.00019	0.00802	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—HPGD—thyroid cancer	0.00019	0.00802	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—MINPP1—thyroid cancer	0.000187	0.00789	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—HPGD—thyroid cancer	0.000177	0.00749	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—HPGD—thyroid cancer	0.000177	0.00749	CbGpPWpGaD
Brinzolamide—CA1—C-MYB transcription factor network—NRAS—thyroid cancer	0.000174	0.00737	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—NDUFA13—thyroid cancer	0.000173	0.0073	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—NDUFA13—thyroid cancer	0.000166	0.007	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—MINPP1—thyroid cancer	0.000164	0.00694	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—HPGD—thyroid cancer	0.000164	0.00694	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—CHST14—thyroid cancer	0.000162	0.00687	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—NDUFA13—thyroid cancer	0.000159	0.00671	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—CHST14—thyroid cancer	0.000156	0.00658	CbGpPWpGaD
Brinzolamide—CA1—C-MYB transcription factor network—KRAS—thyroid cancer	0.00015	0.00634	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—CHST14—thyroid cancer	0.000149	0.00631	CbGpPWpGaD
Brinzolamide—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000145	0.00611	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—NDUFA13—thyroid cancer	0.00014	0.0059	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—CHST14—thyroid cancer	0.000131	0.00555	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—HPGD—thyroid cancer	0.000131	0.00553	CbGpPWpGaD
Brinzolamide—CA1—C-MYB transcription factor network—HRAS—thyroid cancer	0.000128	0.00539	CbGpPWpGaD
Brinzolamide—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000127	0.00539	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—HPGD—thyroid cancer	0.000126	0.00531	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—HPGD—thyroid cancer	0.00012	0.00509	CbGpPWpGaD
Brinzolamide—CA9—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.00012	0.00507	CbGpPWpGaD
Brinzolamide—CA9—Cellular responses to stress—HIF1A—thyroid cancer	0.000118	0.00498	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—TPR—thyroid cancer	0.000112	0.00473	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—PRKAR1A—thyroid cancer	0.00011	0.00465	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—TPR—thyroid cancer	0.000109	0.00461	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—TPR—thyroid cancer	0.000109	0.00461	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—PRKAR1A—thyroid cancer	0.000107	0.00453	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—PRKAR1A—thyroid cancer	0.000107	0.00453	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—HPGD—thyroid cancer	0.000106	0.00447	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—TPR—thyroid cancer	0.000102	0.0043	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—TPR—thyroid cancer	0.000102	0.0043	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—PRKAR1A—thyroid cancer	0.0001	0.00423	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—PRKAR1A—thyroid cancer	0.0001	0.00423	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—TPR—thyroid cancer	9.43e-05	0.00399	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—PRKAR1A—thyroid cancer	9.28e-05	0.00392	CbGpPWpGaD
Brinzolamide—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	8.74e-05	0.00369	CbGpPWpGaD
Brinzolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	8.69e-05	0.00367	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—SLC5A5—thyroid cancer	8.38e-05	0.00354	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—SLC5A5—thyroid cancer	8.16e-05	0.00345	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—SLC5A5—thyroid cancer	8.16e-05	0.00345	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—SLC5A5—thyroid cancer	7.62e-05	0.00322	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—SLC5A5—thyroid cancer	7.62e-05	0.00322	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—TPR—thyroid cancer	7.52e-05	0.00318	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—PRKAR1A—thyroid cancer	7.4e-05	0.00313	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—TPR—thyroid cancer	7.21e-05	0.00305	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—PRKAR1A—thyroid cancer	7.1e-05	0.003	CbGpPWpGaD
Brinzolamide—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	7.08e-05	0.00299	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—SLC5A5—thyroid cancer	7.06e-05	0.00298	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—RXRA—thyroid cancer	7.04e-05	0.00297	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—TPR—thyroid cancer	6.91e-05	0.00292	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—RXRA—thyroid cancer	6.86e-05	0.0029	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—RXRA—thyroid cancer	6.86e-05	0.0029	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—PRKAR1A—thyroid cancer	6.8e-05	0.00287	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—RXRA—thyroid cancer	6.4e-05	0.00271	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—RXRA—thyroid cancer	6.4e-05	0.00271	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—TPR—thyroid cancer	6.08e-05	0.00257	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—PRKAR1A—thyroid cancer	5.98e-05	0.00253	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—RXRA—thyroid cancer	5.93e-05	0.00251	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—SLC5A5—thyroid cancer	5.63e-05	0.00238	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—SLC5A5—thyroid cancer	5.4e-05	0.00228	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—SLC5A5—thyroid cancer	5.18e-05	0.00219	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—RXRA—thyroid cancer	4.73e-05	0.002	CbGpPWpGaD
Brinzolamide—CA9—Cellular responses to stress—TP53—thyroid cancer	4.69e-05	0.00198	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—SLC5A5—thyroid cancer	4.55e-05	0.00192	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—RXRA—thyroid cancer	4.54e-05	0.00192	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—PPARG—thyroid cancer	4.44e-05	0.00188	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—RXRA—thyroid cancer	4.35e-05	0.00184	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—PPARG—thyroid cancer	4.33e-05	0.00183	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—PPARG—thyroid cancer	4.33e-05	0.00183	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—PPARG—thyroid cancer	4.04e-05	0.00171	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—PPARG—thyroid cancer	4.04e-05	0.00171	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—RXRA—thyroid cancer	3.82e-05	0.00162	CbGpPWpGaD
Brinzolamide—CYP3A4—Biological oxidations—RXRA—thyroid cancer	3.76e-05	0.00159	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—PPARG—thyroid cancer	3.75e-05	0.00158	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—PTGS2—thyroid cancer	3.5e-05	0.00148	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—PTGS2—thyroid cancer	3.41e-05	0.00144	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—PTGS2—thyroid cancer	3.41e-05	0.00144	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—PTGS2—thyroid cancer	3.18e-05	0.00134	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—PTGS2—thyroid cancer	3.18e-05	0.00134	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—PTEN—thyroid cancer	3.05e-05	0.00129	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—PPARG—thyroid cancer	2.99e-05	0.00126	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—PTEN—thyroid cancer	2.97e-05	0.00126	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—PTEN—thyroid cancer	2.97e-05	0.00126	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—PTGS2—thyroid cancer	2.95e-05	0.00125	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—PPARG—thyroid cancer	2.86e-05	0.00121	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—PTEN—thyroid cancer	2.77e-05	0.00117	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—PTEN—thyroid cancer	2.77e-05	0.00117	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—MINPP1—thyroid cancer	2.76e-05	0.00117	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—PPARG—thyroid cancer	2.75e-05	0.00116	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—PTEN—thyroid cancer	2.57e-05	0.00109	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—PPARG—thyroid cancer	2.41e-05	0.00102	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.35e-05	0.000993	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—PTGS2—thyroid cancer	2.35e-05	0.000993	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—PTGS2—thyroid cancer	2.25e-05	0.000952	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—CHST14—thyroid cancer	2.21e-05	0.000934	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—PTGS2—thyroid cancer	2.16e-05	0.000913	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—PTEN—thyroid cancer	2.05e-05	0.000866	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—PTEN—thyroid cancer	1.96e-05	0.00083	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—PTGS2—thyroid cancer	1.9e-05	0.000802	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—PTEN—thyroid cancer	1.88e-05	0.000796	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—HPGD—thyroid cancer	1.78e-05	0.000753	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—AKT1—thyroid cancer	1.76e-05	0.000743	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—AKT1—thyroid cancer	1.71e-05	0.000724	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—AKT1—thyroid cancer	1.71e-05	0.000724	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—PTEN—thyroid cancer	1.66e-05	0.0007	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—AKT1—thyroid cancer	1.6e-05	0.000676	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—AKT1—thyroid cancer	1.6e-05	0.000676	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—AKT1—thyroid cancer	1.48e-05	0.000626	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—AKT1—thyroid cancer	1.18e-05	0.000499	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—AKT1—thyroid cancer	1.13e-05	0.000478	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—AKT1—thyroid cancer	1.09e-05	0.000459	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—TPR—thyroid cancer	1.02e-05	0.000432	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.01e-05	0.000425	CbGpPWpGaD
Brinzolamide—CA9—Metabolism—AKT1—thyroid cancer	9.54e-06	0.000403	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—SLC5A5—thyroid cancer	7.66e-06	0.000324	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—RXRA—thyroid cancer	6.44e-06	0.000272	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—PPARG—thyroid cancer	4.06e-06	0.000172	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.2e-06	0.000135	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—PTEN—thyroid cancer	2.79e-06	0.000118	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—AKT1—thyroid cancer	1.61e-06	6.79e-05	CbGpPWpGaD
